See more : CorEnergy Infrastructure Trust, Inc. (CORR-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Avis Budget Group, Inc. (CAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avis Budget Group, Inc., a leading company in the Rental & Leasing Services industry within the Industrials sector.
You may be interested
- Dimeco, Inc. (DIMC) Income Statement Analysis – Financial Results
- Electric Last Mile Solutions, Inc. (ELMS) Income Statement Analysis – Financial Results
- McKesson Corporation (0JZU.L) Income Statement Analysis – Financial Results
- E Lighting Group Holdings Limited (8222.HK) Income Statement Analysis – Financial Results
- Art’s-Way Manufacturing Co., Inc. (ARTW) Income Statement Analysis – Financial Results
Avis Budget Group, Inc. (CAR)
About Avis Budget Group, Inc.
Avis Budget Group, Inc., together with its subsidiaries, provides car and truck rentals, car sharing, and ancillary products and services to businesses and consumers. It operates the Avis brand, that offers vehicle rental and other mobility solutions to the premium commercial and leisure segments of the travel industry; the Budget Truck brand, a local, and one-way truck and cargo van rental businesses with a fleet of approximately 20,000 vehicles, which are rented through a network of approximately 465 dealer-operated and 385 company-operated locations that serve the consumer and light commercial sectors in the continental United States; and the Zipcar brand, a car sharing network. The company also operates various other car rental brands, such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. In addition, it offers optional insurance products and coverages, such as supplemental liability, personal accident, personal effects protection, emergency sickness protection, and automobile towing protection and cargo insurance products; fuel service options, roadside assistance services, electronic toll collection services, curbside delivery, tablet rentals, access to satellite radio, portable navigation units, and child safety seat rentals; automobile towing equipment and other moving accessories, such as hand trucks, furniture pads, and moving supplies; and Business Intelligence solution, an online portal for corporate travel. Avis Budget Group, Inc. operates in approximately 10,400 locations worldwide. The company was formerly known as Cendant Corporation and changed its name to Avis Budget Group, Inc. in September 2006. Avis Budget Group, Inc. was founded in 1946 and is headquartered in Parsippany, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.01B | 11.99B | 9.31B | 5.40B | 9.17B | 9.12B | 8.85B | 8.66B | 8.50B | 8.49B | 7.94B | 7.36B | 5.90B | 5.19B | 5.13B | 5.98B | 6.03B | 5.69B | 18.24B | 19.79B | 18.19B | 14.09B | 8.95B | 3.93B | 5.40B | 5.28B | 5.31B | 2.35B | 1.42B | 1.04B | 875.00M | 738.90M | 641.30M | 450.80M | 365.00M | 268.60M | 195.30M | 138.30M | 84.20M |
| Cost of Revenue | 7.24B | 1.23B | 1.51B | 1.69B | 2.41B | 2.49B | 2.51B | 2.33B | 2.22B | 2.29B | 2.08B | 1.77B | 1.51B | 1.59B | 1.72B | 2.01B | 1.93B | 1.74B | 10.68B | 10.34B | 9.41B | 6.72B | 2.94B | 1.31B | 1.10B | 609.20M | -184.00M | -3.00M | -74.00M | -95.70M | -94.70M | -109.10M | -106.70M | -73.00M | 128.50M | 10.40M | 16.90M | 900.00K | 2.40M |
| Gross Profit | 4.77B | 10.76B | 7.80B | 3.72B | 6.77B | 6.63B | 6.34B | 6.33B | 6.28B | 6.21B | 5.86B | 5.59B | 4.39B | 3.59B | 3.41B | 3.97B | 4.10B | 3.95B | 7.55B | 9.45B | 8.78B | 7.37B | 6.01B | 2.62B | 4.31B | 4.67B | 5.50B | 2.35B | 1.49B | 1.14B | 969.70M | 848.00M | 748.00M | 523.80M | 236.50M | 258.20M | 178.40M | 137.40M | 81.80M |
| Gross Profit Ratio | 39.69% | 89.74% | 83.79% | 68.79% | 73.76% | 72.68% | 71.67% | 73.08% | 73.86% | 73.09% | 73.86% | 75.97% | 74.42% | 69.32% | 66.50% | 66.35% | 68.04% | 69.48% | 41.41% | 47.75% | 48.28% | 52.29% | 67.18% | 66.56% | 79.69% | 88.47% | 103.46% | 100.13% | 105.23% | 109.16% | 110.82% | 114.77% | 116.64% | 116.19% | 64.79% | 96.13% | 91.35% | 99.35% | 97.15% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.49B | 1.28B | 1.06B | 703.00M | 1.24B | 1.22B | 1.12B | 1.13B | 1.09B | 1.08B | 1.02B | 925.00M | 756.00M | 583.00M | 551.00M | 655.00M | 658.00M | 818.00M | 3.78B | 3.58B | 3.12B | 2.51B | 2.01B | 1.07B | 1.69B | 1.82B | 0.00 | 0.00 | 764.30M | 571.10M | 489.50M | 437.00M | 386.90M | 270.50M | 50.50M | 142.00M | 100.70M | 79.80M | 49.60M |
| Selling & Marketing | -81.00M | 64.00M | 81.00M | 54.00M | 121.00M | 116.00M | 111.00M | 127.00M | 123.00M | 112.00M | 116.00M | 127.00M | 0.00 | -14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 1.71B | 2.01B | 1.76B | 1.39B | 1.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.41B | 1.35B | 1.15B | 703.00M | 1.24B | 1.22B | 1.12B | 1.13B | 1.09B | 1.08B | 1.02B | 925.00M | 756.00M | 569.00M | 551.00M | 655.00M | 658.00M | 818.00M | 3.78B | 3.58B | 3.12B | 2.51B | 2.01B | 1.07B | 1.69B | 1.82B | 1.99B | 1.20B | 764.30M | 571.10M | 489.50M | 437.00M | 386.90M | 270.50M | 50.50M | 142.00M | 100.70M | 79.80M | 49.60M |
| Other Expenses | 0.00 | 5.51B | 4.53B | 3.54B | 4.95B | 4.90B | 4.75B | 4.61B | 4.50B | 4.43B | 4.23B | 3.95B | 3.12B | 2.71B | 2.73B | 3.24B | 3.12B | 2.99B | 1.57B | 3.06B | 3.01B | 2.56B | 2.30B | 330.00M | 1.07B | 1.58B | 2.00B | 704.30M | 453.90M | 378.80M | 337.60M | 309.50M | 277.60M | 210.80M | 158.30M | 132.60M | 47.10M | 42.30M | 24.30M |
| Operating Expenses | 1.58B | 6.86B | 5.67B | 4.25B | 6.19B | 6.05B | 5.81B | 5.68B | 5.54B | 5.51B | 5.22B | 4.86B | 3.88B | 3.28B | 3.27B | 3.89B | 3.78B | 3.81B | 5.35B | 6.64B | 6.13B | 5.07B | 4.31B | 1.40B | 2.76B | 3.41B | 3.99B | 1.90B | 1.22B | 949.90M | 827.10M | 746.50M | 664.50M | 481.30M | 208.80M | 274.60M | 147.80M | 122.10M | 73.90M |
| Cost & Expenses | 8.82B | 8.09B | 7.18B | 5.93B | 8.59B | 8.55B | 8.31B | 8.02B | 7.76B | 7.80B | 7.30B | 6.63B | 5.39B | 4.87B | 4.98B | 5.90B | 5.70B | 5.55B | 16.03B | 16.97B | 15.54B | 11.79B | 7.25B | 2.72B | 3.85B | 4.02B | 3.81B | 1.90B | 1.14B | 854.20M | 732.40M | 637.40M | 557.80M | 408.30M | 337.30M | 285.00M | 164.70M | 123.00M | 76.30M |
| Interest Income | 0.00 | 1.00M | 1.00M | 12.00M | 15.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 296.00M | 250.00M | 218.00M | 231.00M | 178.00M | 188.00M | 188.00M | 203.00M | 194.00M | 209.00M | 228.00M | 268.00M | 219.00M | 162.00M | 153.00M | 129.00M | 127.00M | 236.00M | 1.34B | 251.00M | 797.00M | 1.27B | 1.84B | 401.00M | 3.93B | 1.46B | 2.36B | 340.80M | 8.70M | 0.00 | 0.00 | 2.10M | 60.80M | 11.00M | 15.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.45B | 2.81B | 2.48B | 2.56B | 3.14B | 2.23B | 2.21B | 2.13B | 163.00M | 2.02B | 128.00M | 109.00M | 95.00M | 90.00M | 96.00M | 1.73B | 1.65B | 1.47B | 1.29B | 3.20B | 3.46B | 2.72B | 2.17B | 330.00M | 1.07B | 1.58B | 2.00B | 704.30M | 453.90M | 378.80M | 337.60M | 309.50M | 277.60M | 210.80M | 158.30M | 132.60M | 47.10M | 42.30M | 24.30M |
| EBITDA | 6.43B | 7.15B | 4.74B | 2.17B | 3.96B | 2.99B | 2.88B | 2.98B | 794.00M | 2.92B | 477.00M | 693.00M | 350.00M | 332.00M | 172.00M | 841.00M | 1.10B | 1.35B | 1.73B | 1.31B | 6.18B | 5.01B | 3.88B | 1.64B | 4.54B | 3.69B | 4.65B | 1.32B | 729.00M | 569.30M | 475.90M | 407.70M | 383.50M | 250.60M | 187.80M | 116.20M | 74.50M | 54.10M | 31.30M |
| EBITDA Ratio | 53.57% | 34.50% | 25.80% | -5.72% | 8.57% | 8.46% | 8.31% | 9.68% | 10.62% | 31.98% | 9.69% | 11.42% | 10.34% | 7.89% | 4.74% | 30.17% | 32.76% | 28.30% | 24.39% | 30.30% | 33.95% | 38.23% | 51.73% | 41.78% | 84.04% | 69.80% | 87.55% | 56.28% | 51.52% | 54.49% | 54.39% | 55.18% | 59.80% | 55.59% | 51.45% | 42.07% | 38.15% | 39.12% | 37.17% |
| Operating Income | 3.19B | 3.91B | 2.13B | -529.00M | 579.00M | 516.00M | 476.00M | 585.00M | 685.00M | 696.00M | 617.00M | 715.00M | 515.00M | 305.00M | 129.00M | 76.00M | 325.00M | 143.00M | 866.00M | 2.80B | 2.71B | 1.03B | 2.46B | 1.31B | 3.47B | 2.11B | 2.66B | 617.00M | 275.10M | 190.50M | 138.30M | 98.20M | 105.90M | 39.80M | 29.50M | -19.60M | 27.40M | 11.80M | 7.00M |
| Operating Income Ratio | 26.57% | 32.62% | 22.88% | -9.79% | 6.31% | 5.66% | 5.38% | 6.76% | 8.06% | 8.20% | 7.77% | 9.72% | 8.73% | 5.88% | 2.51% | 1.27% | 5.39% | 2.51% | 4.75% | 14.15% | 14.92% | 7.30% | 27.51% | 33.38% | 64.25% | 39.85% | 49.99% | 26.28% | 19.44% | 18.23% | 15.81% | 13.29% | 16.51% | 8.83% | 8.08% | -7.30% | 14.03% | 8.53% | 8.31% |
| Total Other Income/Expenses | -1.28B | -270.00M | -423.00M | -965.00M | -280.00M | -499.00M | -623.00M | -606.00M | -303.00M | -577.00M | -520.00M | -415.00M | -479.00M | -247.00M | -206.00M | -1.42B | -1.32B | -820.00M | -213.00M | 1.77B | -445.00M | -700.00M | -1.05B | -354.00M | -2.18B | -1.00B | -754.70M | -170.40M | -4.40M | 0.00 | -400.00K | -5.40M | -38.40M | -13.70M | -13.90M | 1.80M | 4.00M | 4.30M | -700.00K |
| Income Before Tax | 1.91B | 3.64B | 1.71B | -956.00M | 287.00M | 267.00M | 211.00M | 279.00M | 382.00M | 392.00M | 97.00M | 300.00M | 36.00M | 72.00M | -77.00M | -1.34B | -992.00M | -677.00M | 1.35B | 2.55B | 2.21B | 1.64B | 658.00M | 885.00M | -635.00M | 264.40M | 294.70M | 276.20M | 266.40M | 190.50M | 142.20M | 96.10M | 45.10M | 28.80M | 13.80M | -14.60M | 31.40M | 16.10M | 7.20M |
| Income Before Tax Ratio | 15.94% | 30.32% | 18.34% | -17.70% | 3.13% | 2.93% | 2.38% | 3.22% | 4.49% | 4.62% | 1.22% | 4.08% | 0.61% | 1.39% | -1.50% | -22.47% | -16.46% | -11.90% | 7.38% | 12.88% | 12.15% | 11.62% | 7.35% | 22.52% | -11.75% | 5.00% | 5.54% | 11.76% | 18.83% | 18.23% | 16.25% | 13.01% | 7.03% | 6.39% | 3.78% | -5.44% | 16.08% | 11.64% | 8.55% |
| Income Tax Expense | 279.00M | 880.00M | 425.00M | -272.00M | -15.00M | 102.00M | -150.00M | 116.00M | 69.00M | 147.00M | 81.00M | 10.00M | 65.00M | 18.00M | -30.00M | -219.00M | -45.00M | -226.00M | 474.00M | 728.00M | 745.00M | 556.00M | 235.00M | 309.00M | -406.00M | 104.50M | 239.30M | 112.10M | 103.00M | 72.90M | 54.80M | 37.30M | 20.00M | 11.30M | 5.70M | -3.30M | 14.00M | 7.40M | 4.40M |
| Net Income | 1.63B | 2.76B | 1.29B | -684.00M | 302.00M | 165.00M | 361.00M | 163.00M | 313.00M | 245.00M | 16.00M | 290.00M | -29.00M | 54.00M | -47.00M | -1.12B | -916.00M | -1.99B | 1.34B | 2.08B | 1.17B | 846.00M | 385.00M | 602.00M | -55.00M | 539.60M | 55.40M | 164.10M | 163.40M | 117.60M | 87.40M | 58.80M | 25.10M | 17.50M | 8.10M | -11.30M | 17.40M | 8.70M | 2.80M |
| Net Income Ratio | 13.59% | 23.04% | 13.80% | -12.66% | 3.29% | 1.81% | 4.08% | 1.88% | 3.68% | 2.89% | 0.20% | 3.94% | -0.49% | 1.04% | -0.92% | -18.81% | -15.20% | -35.05% | 7.35% | 10.52% | 6.44% | 6.01% | 4.30% | 15.32% | -1.02% | 10.21% | 1.04% | 6.99% | 11.55% | 11.26% | 9.99% | 7.96% | 3.91% | 3.88% | 2.22% | -4.21% | 8.91% | 6.29% | 3.33% |
| EPS | 42.61 | 58.44 | 19.80 | -9.70 | 4.02 | 2.08 | 4.32 | 1.78 | 3.02 | 2.32 | 0.15 | 2.72 | -0.28 | 0.53 | -0.46 | -11.03 | -8.88 | -19.82 | 15.56 | 20.29 | 11.50 | 7.57 | 4.20 | 8.40 | -0.73 | 6.40 | -2.70 | 4.10 | 5.60 | 4.50 | 3.40 | 2.50 | 1.10 | 1.00 | 0.50 | -0.70 | 1.20 | 0.70 | 0.20 |
| EPS Diluted | 42.06 | 57.11 | 19.44 | -9.70 | 3.99 | 2.06 | 4.25 | 1.75 | 2.98 | 2.22 | 0.15 | 2.42 | -0.28 | 0.49 | -0.46 | -11.03 | -8.88 | -19.82 | 15.56 | 19.66 | 11.30 | 7.57 | 4.10 | 8.10 | -0.73 | 6.10 | -2.70 | 4.10 | 5.60 | 4.50 | 3.40 | 2.50 | 1.10 | 1.00 | 0.50 | -0.70 | 1.20 | 0.70 | 0.20 |
| Weighted Avg Shares Out | 38.30M | 47.30M | 64.90M | 70.50M | 75.20M | 79.30M | 83.40M | 92.00M | 103.40M | 105.40M | 107.60M | 106.60M | 105.20M | 103.10M | 102.20M | 101.90M | 103.10M | 100.60M | 104.00M | 103.10M | 101.91M | 111.76M | 91.67M | 71.67M | 75.10M | 84.38M | 80.44M | 40.02M | 29.18M | 26.13M | 25.71M | 23.52M | 22.82M | 17.50M | 16.20M | 16.14M | 14.50M | 12.43M | 14.00M |
| Weighted Avg Shares Out (Dil) | 38.80M | 48.40M | 66.10M | 70.50M | 75.70M | 80.10M | 84.80M | 93.30M | 105.00M | 110.60M | 111.40M | 121.60M | 105.20M | 126.70M | 102.20M | 101.90M | 103.10M | 100.60M | 104.00M | 103.10M | 103.72M | 111.76M | 93.90M | 74.32M | 75.10M | 88.52M | 80.44M | 40.02M | 29.18M | 26.13M | 25.71M | 23.52M | 22.82M | 17.50M | 16.20M | 16.14M | 14.50M | 12.43M | 14.00M |
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md. , June 4, 2024...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles)...
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data supporting...
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new and updated data from the CARTITUDE clinical development program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be...
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif. , May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention...
Higher inflation in 2024 likely: NABE
Inflation is likely to stick around at higher-than-desired levels for the rest of the year, according to a new survey by America’s top economists. "With the higher inflation expectations, panelists now anticipate the Federal Reserve’s Open Market Committee will cut...
Meridian Wealth Management LLC Sells 3,300 Shares of PACCAR Inc (NASDAQ:PCAR)
Meridian Wealth Management LLC trimmed its holdings in shares of PACCAR Inc (NASDAQ:PCAR – Free Report) by 49.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,368...
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for...
National Bank of Canada FI Grows Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
National Bank of Canada FI boosted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 200.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The...
Source: https://incomestatements.info
Category: Stock Reports